Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer
Completed
- Conditions
- Gastric Cancer
- Registration Number
- NCT02274376
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 223
Inclusion Criteria
- Patients aged >/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (first-line chemotherapy)
- Informed consent
Read More
Exclusion Criteria
- Contraindications to Xeloda per the Summary of Product Characteristics (SmPC)
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival Up to 4 years Safety and tolerability: incidence and nature of adverse drug reactions Up to 4 years
- Secondary Outcome Measures
Name Time Method Proportion of patients with modifications in Xeloda dosing Up to 4 years Average duration of treatment Up to 4 years Number of modifications in chosen regimen combination therapy Up to 4 years Incidence and nature of dose interruptions Up to 4 years